Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1987-09-04
1990-04-17
Rollins, John W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
A61K 3170
Patent
active
049180606
ABSTRACT:
A method of treating a disorder of receptors involving mediation by endocytosis which comprises administering to a host suffering from said disorder, an effective amount of 3-deazaadenosine or periodate-oxidized adenosine.
REFERENCES:
patent: 4148888 (1979-04-01), Cantoni et al.
patent: 4322411 (1982-03-01), Vinegar et al.
patent: 4335040 (1982-06-01), Livingston
patent: 4347315 (1982-08-01), Krenitsky et al.
Kuncl et al; Proc. Natl. Acad. Sci. USA, vol. 85, pp. 4032-4036, Jun. 1988; "Inhibition of Methyltransferase Reduces the Turnover of Acetylcholine Receptors".
Fambrough et al; Science, vol. 182, pp. 293-295, Oct. 19, 1973; "Neuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine Receptors".
Pestronk et al; Brain Research, 412 (1987), pp. 302-310; "Mechanism of Action of Lithium on Acetylcholine Receptor Metabolism in Skeletal Muscle".
Toyka et al; New England Journal of Medicine (reprinted from) 296:125-131 (Jan. 20), 1977; "Myasthenia Gravis-Study of Humoral Immune Mechanisms by Passive Transfer to Mice".
Jerald L. Hoffman; Usdin, Borchardt, Creveling, eds. Transmethylation; pp. 181-186; "Inhibition of S-Adenosyl Sulfur Amino Acid Metabolism: Periodate-Oxidized Nucleosides as Potent Inhibitors of S-Adenosylhomocysteine Hydrolase".
Christian de Duve; Eur. J. Biochem. 137, 391-397 (1983); "Sysosomes Revisted".
Mark Marsh; Biochem. J. (1984), vol. 218, pp. 1-10; "Review Article-The Entry of Enveloped Viruses into Cells by Endocytosis".
Blecher et al; Receptors and Human Disease; Williams & Wilkins, Balto/London, 1981; Chapter 5; Insulin Receptors: Miscellaneous Disorders; pp. 77-94.
Kahn et al; Receptors, Antibodies and Disease, CIBA Foundation Symposium 90, 1982, Pitman, London; "Autoantibodies to Insulin Receptors in Man: Immunological Determinants and Mechanism of Action".
Maddon et al; Cell; vol. 47, pp. 333-348, Nov. 17, 1986; The T4 Gene Encodes the Aids Virus Receptor and is Expressed in the Immune System and the Brain.
Medzihradsky, Regulatory Role for the Immune Complex in Modulation of Phagocytosis by 3-Deazaadenosine, The Journal of Immunology, vol. 133, No. 2, pp. 946-949.
Montgomery et al, Carbocyclic Analogue of 3-Deazaadenosine: A Novel Antiviral Agent Using S-Adenosylhomocysteine Hydrolase as a Pharmacological Target.
Bader et al., 3-Deazaadenosine, an Inhibitor of Adenosylhomocysteine Hydrolase, Inhibits Reproduction of Rous Sarcoma Virus . . . , Virology 89, 494-505 (1978).
Backlund et al., Effects of the S-Adenosylhomocysteine Hydrolase . . . , Eur. Biochem. 160, pp. 245-251 (1986).
Lentz, Binding of Viral Attachment Protein to Host-Cell Receptor: The Achilles Heel of Infectious Viruses, Trends in Pharmacological Sciences, Jul. 1988, vol. 9, No. 7.
M. Blecher et al., Introduction to Receptors, in Receptors and Human Disease, Williams and Wilkins, 1981, pp. 1-23.
Boyle et al, the Chemical Abstracts, 97:107628r (1982).
Finbloom et al, the Chemical Abstracts, 106:17488e (1987).
Medzihradsky et al, the Chemical Abstracts 107:5565a (1987).
Drachman Daniel B.
Kuncl Ralph W.
Rollins John W.
The Johns Hopkins University
LandOfFree
Method of treating myasthenia gravis and related diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating myasthenia gravis and related diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating myasthenia gravis and related diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1052815